GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Ultragenyx Pharmaceutical
Ultragenyx is a biopharmaceutical company focused on treating ultra-rare genetic diseases. Its stock price reflects the success of its drug commercialization. It's a story where a single drug for a small group of patients can generate hundreds of millions of dollars in revenue.
Share prices of companies in the market segment - Dna
Ultragenyx is a biopharmaceutical company focused on treating ultra-rare genetic diseases. We classify it as part of the DNA therapeutics sector, and the chart below reflects the general trends and investor sentiment in this cutting-edge field of biotechnology.
Broad Market Index - GURU.Markets
Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases. Its focus on innovation makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Ultragenyx compares to it.
Change in the price of a company, segment, and market as a whole per day
RARE - Daily change in the company's share price Ultragenyx Pharmaceutical
Ultragenyx, a rare disease company, has high volatility, as measured by change_co. This indicator reflects the market's reaction to clinical trial results—key events for biotech. At System.GURU.Markets, this value is essential for formulas assessing the risk and potential for breakthroughs in the sector.
Daily change in the price of a set of shares in a market segment - Dna
Ultragenyx Pharmaceutical Inc. is a leader in the treatment of rare genetic diseases. This chart illustrates the high volatility of the biotech sector. Comparing it to RARE's performance helps us understand the extent to which its portfolio of orphan drugs makes it more or less sensitive to overall industry trends.
Daily change in the price of a broad market stock, index - GURU.Markets
Ultragenyx is a biopharmaceutical company specializing in drugs for the treatment of rare and ultra-rare genetic diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Ultragenyx's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Ultragenyx Pharmaceutical
Ultragenyx is a leading biotech company specializing in the treatment of rare genetic diseases. Its year-over-year performance reflects the commercial success of its drugs and investor confidence in its R&D platform.
Annual dynamics of market capitalization of the market segment - Dna
Ultragenyx Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing drugs for the treatment of ultra-rare diseases. Its expertise in this complex niche is its key advantage. The chart shows how its diversified portfolio and scientific advancements influence its performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ultragenyx, which specializes in drugs for rare diseases, operates in a non-cyclical sector. Demand for its drugs is unaffected by the economic climate. The company's share price performance is driven by its success in research and commercialization, making it a growth story isolated from general market cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Ultragenyx Pharmaceutical
The performance of Ultragenyx, a biopharmaceutical company focused on rare diseases, depends on its product cycle. The monthly fluctuations on the chart reflect sales data for its approved drugs and, more importantly, news about clinical trials of new candidates, which underpin its long-term growth.
Monthly dynamics of market capitalization of the market segment - Dna
Ultragenyx Pharmaceutical is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of ultra-rare genetic diseases. Its sector dynamics, shown in the chart, reflect high risks. This allows us to assess how its focus on diseases with high unmet need and its diversified portfolio influence its strategy.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ultragenyx is a biopharmaceutical company focused on treating rare (orphan) genetic diseases. Shares of companies like this are driven by anticipation of clinical trial data. The chart below shows how Ultragenyx's performance has been out of sync with the broader market, driven by specific news.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Ultragenyx Pharmaceutical
Shares of Ultragenyx Pharmaceutical, which focuses on treating rare genetic diseases, are extremely volatile. Weekly price movements depend entirely on clinical trial results, regulatory decisions, and news of gene therapy breakthroughs. The chart below illustrates how short-term scientific events shape biotech valuations.
Weekly dynamics of market capitalization of the market segment - Dna
How unique is Ultragenyx's performance in the biotech sector? This chart compares the rare disease-focused company's weekly stock price movements with the overall trend. This helps us understand whether its sharp movements are a unique reaction to gene therapy news or reflect broader sentiment across the volatile sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Ultragenyx Pharmaceutical specializes in treating ultra-rare genetic diseases. This chart shows how its weekly performance is unaffected by the market. The success or failure of a single drug can cause massive stock price movements, while the S&P 500 remains stable.
Market capitalization of the company, segment and market as a whole
RARE - Market capitalization of the company Ultragenyx Pharmaceutical
The price chart of Ultragenyx Pharmaceutical reflects the expectations for its drugs for treating rare and ultra-rare genetic diseases. This biotech company's market capitalization is directly dependent on clinical trial success and regulatory approval. The dynamics show how investors value its orphan drug portfolio.
RARE - Share of the company's market capitalization Ultragenyx Pharmaceutical within the market segment - Dna
Ultragenyx Pharmaceutical specializes in developing drugs for rare and ultra-rare genetic diseases. Its share of the biotech sector's market capitalization reflects the high value of its drugs, which target small groups of patients with unmet needs. The chart shows how approvals and sales of new drugs shape its industry weight.
Market capitalization of the market segment - Dna
Here's a chart of the total market capitalization of biotech companies focused on ultra-rare diseases. Ultragenyx Pharmaceutical is a leader in this complex but vital niche. The graph shows how the market values the company's ability to discover and commercialize drugs for small patient populations.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes hope for people with rare genetic diseases. Ultragenyx Pharmaceutical's market capitalization is the market valuation of its portfolio of orphan disease drugs. The dynamics demonstrate how a focus on niche yet critically important therapies creates enormous value in the global pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
RARE - Book value capitalization of the company Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical's book value represents its scientific capital, which is focused on combating rare genetic diseases. The chart below reflects the value of its pipeline of developments, patents, and technologies. Growth in this pipeline signals success in clinical trials, which form its main asset and offer hope to patients.
RARE - Share of the company's book capitalization Ultragenyx Pharmaceutical within the market segment - Dna
For Ultragenyx, which focuses on rare genetic diseases, its tangible assets are not so much its factories as its advanced R&D and manufacturing capabilities for creating complex biologics. The chart shows its share of this highly specialized scientific and manufacturing infrastructure.
Market segment balance sheet capitalization - Dna
Ultragenyx is a biopharmaceutical company focused on rare diseases. It not only develops but also manufactures some of its drugs, making it more capital-intensive than a pure R&D startup. The graph will show whether this mixed model (science and manufacturing) is the norm for the entire biopharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
Ultragenyx's balance sheet is dedicated to developing drugs for rare and ultra-rare genetic diseases. The company's assets are a financial resource that offers hope to patients with diagnoses unavailable to large pharmaceutical companies. The chart illustrates the scale of these targeted investments in science.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical develops drugs for rare and ultra-rare genetic diseases. The company has virtually no tangible assets. Its market capitalization is a valuation of its scientific portfolio and the commercial potential of its drugs for very small patient groups. The chart shows how the hope of saving lives creates enormous shareholder value.
Market to book capitalization ratio in a market segment - Dna
Ultragenyx Pharmaceutical specializes in drugs for the treatment of rare genetic diseases. The company's value is almost entirely dependent on its pipeline of developments and patents. This chart clearly demonstrates how market capitalization, based on hopes, is many times greater than the value of its tangible assets.
Market to book capitalization ratio for the market as a whole
Ultragenyx Pharmaceutical is a biotech company focused on developing drugs for rare genetic diseases. The chart illustrates how the market values the hope of saving lives. The company's market capitalization is based solely on the potential of its scientific developments and has no connection to its tangible assets, which is typical for innovative biotech companies.
Debts of the company, segment and market as a whole
RARE - Company debts Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical specializes in developing drugs for rare genetic diseases. This is one of the riskiest and most expensive areas in pharmaceuticals. Debt helps the company finance its vital but lengthy clinical programs, as this graph, which charts the path from science to cure, demonstrates.
Market segment debts - Dna
Ultragenyx Pharmaceutical specializes in developing drugs for rare and ultra-rare genetic diseases. This is one of the most complex and risky areas in the pharmaceutical industry. This chart shows common financial metrics for the biotech sector, highlighting Ultragenyx's strategy for raising capital to fund its unique and vital research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical specializes in developing drugs for rare and ultra-rare genetic diseases. This is an area with high R&D costs and a small patient base. This chart shows how reliant the company is on external financing, including debt, to bring its life-saving but expensive drugs to market.
Market segment debt to market segment book capitalization - Dna
Ultragenyx Pharmaceutical focuses on developing drugs for rare genetic diseases, one of the most complex and expensive areas in pharmaceuticals. This chart compares the company's debt raised for research to the total market capitalization of the entire DNA therapeutics sector. It demonstrates the scale of its mission to save lives.
Debt to book value of all companies in the market
Ultragenyx Pharmaceutical develops drugs for rare diseases, which requires huge and risky investments. This chart compares the company's debt to the total book value of the entire economy. It shows how large the company's financial stakes in science are relative to the overall size of the stock market that finances it.
P/E of the company, segment and market as a whole
P/E - Ultragenyx Pharmaceutical
This metric for Ultragenyx Pharmaceutical, a company specializing in the treatment of rare genetic diseases, reflects a high assessment of its scientific potential. In the world of biopharma, value is often determined not by current profits, but by hopes for future breakthrough drugs. The chart demonstrates investors' faith in the company's ability to help patients and commercialize its developments.
P/E of the market segment - Dna
This metric represents the average valuation for the biotech sector in which Ultragenyx operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding rare disease treatments and serves as a benchmark.
P/E of the market as a whole
Ultragenyx Pharmaceutical specializes in developing drugs to treat rare and ultra-rare genetic diseases. The company tackles the most complex medical challenges where unmet needs are extremely high. This risk appetite chart helps understand how investors generally evaluate biotech companies with high risk and potential.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical specializes in developing drugs to treat rare and ultra-rare genetic diseases. This chart shows investor expectations regarding the success of clinical trials and the commercial potential of its drugs. It represents the market's assessment of the company's ability to bring hope to patients and profit to shareholders.
%20P%2FE%20Ultragenyx%20Pharmaceutical&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Ultragenyx-Pharmaceutical&v=1772696469664 "Chart of the company's future (projected) P/E Ultragenyx Pharmaceutical")
Future (projected) P/E of the market segment - Dna
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the development and commercialization of new drugs for the treatment of rare and ultra-rare genetic diseases. The company has a diversified portfolio of products and developments. This chart shows overall market sentiment towards the biotech sector, helping to assess Ultragenyx's potential in its complex niche.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772696469709 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Ultragenyx Pharmaceutical is a biotechnology company specializing in developing treatments for ultra-rare genetic diseases. Demand for its products is inelastic, as they save lives. The company's valuation is determined by its scientific success, not by general market expectations.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772696469795 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of rare and ultra-rare genetic diseases. Its cash flows consist of revenue from approved drugs and significant R&D expenditures for new ones. This chart shows the balance between current profits and investments in the future drug portfolio.
Profit of companies in the market segment - Dna
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of rare and ultra-rare genetic diseases. This chart shows the profitability of its niche segment. R&D costs are enormous, but successfully launching even a single drug for a small group of patients can generate high profitability and set the tone for the entire niche.
Overall market profit
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing drugs for rare genetic diseases. Its value is generated in laboratories and depends on the success of clinical trials. While this chart reflects the cyclical fluctuations of the economy, Ultragenyx is working to develop breakthrough treatments whose value is independent of market conditions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of rare and ultra-rare genetic diseases. This chart reflects analysts' earnings expectations, which depend on sales of existing drugs and the success of clinical trials of new candidates. It demonstrates the market's confidence in the company's scientific potential.
%20profit%20of%20the%20company%20Ultragenyx%20Pharmaceutical&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Ultragenyx-Pharmaceutical&v=1772696470029 "Graph of future (projected) profit of the company Ultragenyx Pharmaceutical")
Future (predicted) profit of companies in the market segment - Dna
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the development and commercialization of new treatments for rare and ultra-rare genetic diseases. This chart shows profitability forecasts for the DNA pharmaceutical segment. It reflects expectations for breakthroughs in gene therapy and the market's willingness to pay for innovative drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772696470044 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Ultragenyx Pharmaceutical specializes in developing drugs for rare genetic diseases. It's a capital-intensive business dependent on successful research. The overall market profit forecast shown here influences investors' risk appetite. Positive market conditions facilitate the financing Ultragenyx needs to bring its life-saving drugs to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772696470145 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical is a biopharmaceutical company specializing in the treatment of ultra-rare genetic diseases. With its existing products on the market, the P/S ratio reflects how investors view the commercial success of its drugs and the potential for future developments in this highly profitable niche.
P/S market segment - Dna
Ultragenyx Pharmaceutical specializes in developing treatments for rare (orphan) genetic diseases. These drugs are priced very high, ensuring significant revenue even with a small patient base. The chart shows the premium investors are willing to pay for their focus on niche markets with high unmet needs.
P/S of the market as a whole
Ultragenyx Pharmaceutical specializes in developing drugs for rare (orphan) genetic diseases. Revenue from approved drugs supports research into new ones. This chart illustrates the average revenue estimate, which helps understand the market premium this biotech company receives for innovation and operating in a niche with high unmet needs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical specializes in developing drugs to treat ultra-rare genetic diseases. Its business model is based on high drug prices for small patient groups. This chart shows how the market values its portfolio's future revenue, factoring in the potential for new approvals and expanded use of existing drugs.
%20P%2FS%20Ultragenyx%20Pharmaceutical&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Ultragenyx-Pharmaceutical&v=1772696470313 "The graph of the company's future (projected) P/S Ultragenyx Pharmaceutical")
Future (projected) P/S of the market segment - Dna
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing and commercializing novel treatments for rare and ultra-rare genetic diseases. This chart shows how the market assesses the future commercial potential of its drug portfolio compared to other companies working in the field of DNA therapeutics and rare diseases.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772696470392 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Ultragenyx Pharmaceutical specializes in developing drugs for rare (orphan) genetic diseases. This is a high-risk but potentially highly profitable segment of the pharmaceutical industry. This chart shows revenue expectations for the entire market, and Ultragenyx demonstrates how investors are betting on breakthroughs in genetics that could create entirely new markets and treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772696470408 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the development and commercialization of new drugs for the treatment of rare and ultra-rare genetic diseases. This chart shows revenue from sales of its already approved drugs. Sales growth is directly dependent on the successful launch of new drugs and increased patient access to treatment.
Sales of companies in the market segment - Dna
Ultragenyx Pharmaceutical specializes in developing drugs for rare and ultra-rare genetic diseases. This chart breaks down sales by its commercialized drugs. Investors can see which products are blockbusters and the primary source of revenue, funding further research.
Overall market sales
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases. Its success depends entirely on scientific innovation and regulatory approval. This overall market performance chart is irrelevant to the evaluation of a company whose mission is to save lives.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical specializes in developing drugs for the treatment of rare and ultra-rare genetic diseases. Its revenue forecast depends on the successful commercialization of its drugs and the results of clinical trials. This chart shows how analysts assess the potential of its portfolio to transform patients' lives and generate revenue.
%20sales%20of%20the%20company%20Ultragenyx%20Pharmaceutical&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Ultragenyx-Pharmaceutical&v=1772696470658 "Schedule of future (projected) sales of the company Ultragenyx Pharmaceutical")
Future (projected) sales of companies in the market segment - Dna
Ultragenyx Pharmaceutical specializes in developing drugs to treat rare genetic diseases. This chart shows projected revenue for the gene therapy segment. It allows investors to assess the size and growth analysts expect of this cutting-edge market, which is critical to the commercial prospects of Ultragenyx's innovative drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772696470699 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Ultragenyx Pharmaceutical is a biotechnology company focused on developing drugs to treat rare and ultra-rare genetic diseases. Demand for its products is not dependent on economic cycles. However, the overall market situation, shown in this chart, influences the investment climate and investor willingness to fund expensive biotechnology research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772696470850 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical specializes in developing drugs for rare and ultra-rare genetic diseases. This chart reflects the company's financial trajectory in this complex niche. The ability to convert revenue into profit depends on successfully commercializing very expensive drugs for small patient populations and managing high R&D costs.
Market segment marginality - Dna
Ultragenyx Pharmaceutical specializes in developing treatments for ultra-rare genetic diseases. This chart shows the commercial returns from its unique business model. Its exceptionally high profitability demonstrates the enormous value its drugs provide to patients and its ability to price them accordingly.
Market marginality as a whole
Ultragenyx Pharmaceutical specializes in developing drugs to treat ultra-rare genetic diseases. The company's business model is built on creating treatments for very small patient groups at very high prices. This overall profitability chart shows average values, while Ultragenyx operates in a niche where the economic rules are completely different.
Employees in the company, segment and market as a whole
Number of employees in the company Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical is a biopharmaceutical company specializing in developing treatments for rare genetic diseases. Its staff consists primarily of scientists and clinical trial specialists. The team's growth, visible in the chart, signals progress in developing and bringing life-saving drugs to market.
Share of the company's employees Ultragenyx Pharmaceutical within the market segment - Dna
Ultragenyx Pharmaceutical specializes in the development and commercialization of treatments for rare and ultra-rare genetic diseases. This chart highlights the concentration of unique scientific expertise. It demonstrates the proportion of leading geneticists and researchers working on breakthrough therapies for patients with orphan diseases that Ultragenyx brings together.
Number of employees in the market segment - Dna
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing treatments for rare genetic diseases. This chart shows employment in the DNA research and gene therapy sector. The growing number of scientists in this cutting-edge field demonstrates significant progress and investment in finding cures for previously incurable diseases.
Number of employees in the market as a whole
Ultragenyx Pharmaceutical specializes in developing drugs for rare and ultra-rare genetic diseases. The growth of its team of scientists and doctors is not a reflection of the overall economic situation, but the result of scientific breakthroughs and investments in saving lives. The company represents a sector where value is created not by scale, but by unique knowledge.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Ultragenyx Pharmaceutical (RARE)
Ultragenyx is a biotech company focused on treating rare genetic diseases. Their value is determined by their portfolio of approved drugs and promising developments. This chart shows that even with commercial products, biotech companies maintain the highest cost per employee due to the enormous value of their intellectual property (patents).
%20of%20the%20company%20Ultragenyx%20Pharmaceutical%20(RARE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Ultragenyx-Pharmaceutical-RARE&v=1772696471280 "Chart of market capitalization per employee (in thousands of dollars) of the company Ultragenyx Pharmaceutical (RARE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Ultragenyx is a biotech company focused on treating ultra-rare genetic diseases. They have approved drugs. This chart shows the industry average. It helps estimate the enormous market value generated by the R&D and commercial teams working in this highly complex niche, measured per employee.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772696471424 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Ultragenyx Pharmaceutical is a biotechnology company specializing in developing drugs for rare and ultra-rare genetic diseases. The company's value lies in its scientific pipeline. This chart reflects investors' high hopes that its small but highly qualified team of scientists will be able to create life-saving treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772696471550 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical is a biotech company focused on treating rare (orphan) and ultra-rare genetic diseases. The company has approved drugs. This chart shows the commercial success of their expensive, niche drugs and whether their revenues can cover their high R&D and personnel costs.
%20Chart%20Ultragenyx%20Pharmaceutical%20(RARE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Ultragenyx-Pharmaceutical-RARE&v=1772696471639 "Company Profit Per Employee (in thousands of dollars) Chart Ultragenyx Pharmaceutical (RARE)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Ultragenyx is a biotech company focused on treating "ultra-rare" (orphan) genetic diseases. This chart shows the benchmark for "Specialty Pharma." In this sector, the benchmark for profit per employee is either deeply negative (at the R&D stage) or astronomically high (when a blockbuster drug is approved).
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772696471713 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Ultragenyx is a biopharmaceutical company focused on developing drugs to treat extremely rare (orphan) genetic diseases. This is high-risk R&D. This metric, which illustrates the average profitability per employee in the economy, begs the question: how does the rare disease treatment sector, where RARE operates, compare to average profitability?
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772696471765 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical, a company focused on treating rare genetic diseases, demonstrates the high value of its innovations in this chart. After a drug is launched, revenue per employee becomes very high, reflecting the company's ability to address unmet medical needs with breakthrough technologies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Ultragenyx-Pharmaceutical-RARE&v=1772696471818 "Sales chart per company employee Ultragenyx Pharmaceutical (RARE)")
Sales per employee in the market segment - Dna
Ultragenyx Pharmaceutical is a biotech company focused on treating ultra-rare genetic diseases. The company already has commercially available drugs. This chart shows the average revenue per employee in this segment. It allows one to assess how productive the RARE team (research and commercial) is compared to other companies in the orphan disease niche.
Sales per employee for the market as a whole
Ultragenyx Pharmaceutical (RARE) specializes in treating ultra-rare (orphan) diseases. The company already has commercially available drugs. This chart shows how successfully the company is selling these very expensive medications. Given the small patient population, the sales team must be as efficient as possible, and this indicator measures that.
Short shares by company, segment and market as a whole
Shares shorted by company Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical is a biotech company specializing in the treatment of ultra-rare (orphan) genetic diseases. Their drug prices are astronomical. This chart highlights concerns about their model. "Bearers" may be betting on the failure of new drugs in development or that payers (insurers and governments) will increase pressure on pricing.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Ultragenyx-Pharmaceutical-RARE&v=1772696471958 "Short Shares Chart for the Company Ultragenyx Pharmaceutical (RARE)")
Shares shorted by market segment - Dna
Ultragenyx Pharmaceutical is a biotech company specializing in the treatment of rare (orphan) genetic diseases. This niche market is characterized by very expensive drugs. This chart highlights the pessimism in the biotech sector. The rise in short positions across the industry reflects investor concerns about government pressure on the prices of ultra-expensive drugs, which poses a risk to the entire industry.
Shares shorted by the overall market
Ultragenyx (RARE) is a biotech company specializing in developing treatments for rare (orphan) genetic diseases. This chart illustrates the overall market pessimism. Although their niche isn't dependent on the economy, investors tend to avoid biotech during periods of fear (as the chart illustrates). They may fear that the healthcare system will put downward pressure on the prices of ultra-expensive orphan drugs during a crisis.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical focuses on developing drugs to treat rare genetic diseases. The stock is volatile and dependent on R&D. A chart reading above 70 may reflect positive trial data or FDA approval. Oversold territory (<30) is often associated with research setbacks, regulatory delays, or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Ultragenyx-Pharmaceutical-RARE&v=1772696472132 "RSI 14 indicator chart for the company's stock Ultragenyx Pharmaceutical (RARE)")
RSI 14 Market Segment - Dna
Ultragenyx Pharmaceutical is a biotech company focused on developing treatments for rare and ultra-rare genetic diseases. This is a high-risk sector with the potential for huge breakthroughs. This chart tracks the overall sentiment in the niche biotech sector focused on rare diseases. It helps distinguish news from RARE itself from the general industry hype.
RSI 14 for the overall market
Ultragenyx, a biotech focused on ultra-rare diseases, is critically dependent on this curve. In moments of euphoria, investors are willing to fund risky but humanitarian R&D projects. In moments of panic, the window for raising capital closes, and investors begin to doubt the profitability of drugs for very small patient groups.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RARE (Ultragenyx Pharmaceutical)
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of rare (orphan) genetic diseases. This chart shows the average target price. Analyst forecasts are based on sales of already approved drugs and an assessment of the potential of new gene therapies in development.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RARE-Ultragenyx-Pharmaceutical&v=1772696472358 "A chart showing analyst consensus forecasts for the expected stock price. RARE (Ultragenyx Pharmaceutical)")
The difference between the consensus estimate and the actual stock price RARE (Ultragenyx Pharmaceutical)
Ultragenyx is a biotech company focused on developing and commercializing drugs to treat very rare (ultra-rare) genetic diseases. This chart shows how analysts assess their R&D pipeline and the commercial potential of their expensive but life-saving drugs. It reflects the gap between their target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RARE-Ultragenyx-Pharmaceutical&v=1772696472413 "A chart showing the difference between the consensus forecast and the actual stock price. RARE (Ultragenyx Pharmaceutical)")
Analyst consensus forecast for stock prices by market segment - Dna
Ultragenyx is a biotech company focused on *ultra-rare* genetic diseases. This is a market with very high drug prices but complex R&D. This chart shows analysts' overall expectations for the entire DNA therapeutics sector. It reflects whether experts believe in the commercial success of treating rare diseases.
Analysts' consensus forecast for the overall market share price
Ultragenyx (RARE) is a biotech company focused on developing treatments for ultra-rare (orphan) genetic diseases. They take on diseases neglected by others. This chart shows the overall risk appetite, reflecting the market's willingness to fund expensive and risky developments for very small patient groups.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Ultragenyx Pharmaceutical
Ultragenyx is a biotech company focused on developing and commercializing drugs to treat ultra-rare genetic diseases. This chart is an assessment of their pipeline. It likely reflects the growth rate of their approved drugs and investors' confidence in their extensive R&D pipeline, which targets diseases ignored by others.
AKIMA Market Segment Index - Dna
Ultragenyx (RARE) is a biotech leader focused entirely on the development and commercialization of drugs for ultra-rare genetic diseases. This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark provides insight into how RARE's niche (ultra-rare diseases) R&D strategy differentiates it from the average pharmaceutical company.
The AKIM Index for the overall market
Ultragenyx (RARE) is a biotech company focused on developing drugs for ultra-rare genetic diseases. It's a high-risk scientific bet. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding companies like RARE.
